Tag Archive | "melanoma recurrence"

BMS’ Opdivo cuts risk of melanoma recurrence

Source: Pharma Times, June 2018

Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning at 24 months versus Yervoy.
According to data from the Phase III CheckMate-238 study, presented at this year’s American Society of Clinical Oncology meeting, at 24 months nearly two thirds (63 percent) of patients treated with Opdivo (nivolumab) had longer recurrent-free survival, compared to those treated with Yervoy (ipilimumab; 50 percent) regardless of BRAF mutation status.
The drug also showed an advantage on tolerability, showing a lower rate of serious adverse events (AEs) of any grade compared to Yervoy (17.5 percent versus 40.4 percent, respectively) after 18 months’ treatment.
read the original full article

Posted in Melanoma News, Of InterestComments Off on BMS’ Opdivo cuts risk of melanoma recurrence